Thermo Fisher Scientific Partners With OpenAI to Accelerate Drug Development Through AI Integration

Thermo Fisher Scientific Inc., the global leader in serving science, has announced a strategic collaboration with OpenAI to integrate artificial intelligence (AI) into key areas of its operations. The partnership aims to accelerate drug development, enhance productivity, and reduce costs, enabling customers to bring life-saving therapies to patients faster. By leveraging OpenAI’s advanced models, Thermo Fisher intends to strengthen its innovation pipeline and streamline complex research processes.

“AI is shaping the future of science. And when combined with our Mission to enable our customers to make the world healthier, cleaner and safer, it is a powerful catalyst to accelerate scientific advancement,” said Marc Casper, Chairman, President and Chief Executive Officer, Thermo Fisher Scientific. “With OpenAI, we’re further embedding AI across our operations, products and services. Together, we’re building an ecosystem that accelerates scientific breakthroughs and delivers impact for customers, patients and society.”

As part of the initiative, OpenAI’s APIs will be embedded across Thermo Fisher’s business functions, including product development, service delivery, customer engagement, and operational efficiency. A major focus will be on Thermo Fisher’s PPD™ clinical research business, where AI will be used to shorten clinical trial timelines, optimize data analysis, and improve decision-making, leading to faster market entry for new drugs and meaningful value creation across the pharmaceutical ecosystem.

“Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people,” said Brad Lightcap, chief operating officer at OpenAI. “With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients' lives."

The collaboration will also see AI integration into Thermo Fisher’s Accelerator™ Drug Development solution, a comprehensive offering that covers early development through commercialization. Additionally, Thermo Fisher plans to introduce ChatGPT Enterprise to its workforce, equipping teams with advanced AI tools to boost collaboration and confidence in adopting cutting-edge technologies. Together, Thermo Fisher and OpenAI aim to reshape the future of scientific research and drug development through scalable, intelligent automation.